Search results for: COVID-19 | Wyss Institute

Wyss Institute Search Site

Technologies 6

Broad-Spectrum RNA Therapeutic for COVID-19 and Influenza
The COVID-19 pandemic has killed more than two million people worldwide and death tolls continue to mount due to the lack of an effective prevention, cure, or widespread vaccine for the disease. Influenza viruses have been even more deadly in the past, and still cause hundreds of thousands of deaths every year. Seasonal flu vaccines...
OMNIVAX: Broadly Deployable Infection Vaccine Platform
OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases.
Using Systems Biology to Find and Test New Drugs Faster
The pharmaceutical industry is infamous for big numbers: it takes 10-15 years and can cost over $2 billion to bring a new drug from the lab to the market. Up to 6 of those years and $1 billion are spent in laborious preclinical trials to identify and validate new potential drug compounds, and much of...
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Diseases
Microbial infection is the cause of life-threatening cases of sepsis, meningitis and multiple other diseases that are major causes of death world-wide. Equally prevalent are pathogenic contaminants in our environment, food, and manufacturing processes. In each case, the presence of dangerous microbes must be confirmed, and when they are found, they need to be removed,...
INSPECTR™: Direct-to-Consumer Molecular Diagnostic
Molecular diagnostics is the fastest growing segment of the global in vitro diagnostics market. There remains a gap, however, in providing this technology directly to consumers in a format that is as cost effective and as simple to use as a lateral flow immunoassay, like glucose and pregnancy tests. Scientists at the Wyss Institute have...
Human Organs-on-Chips
Clinical studies take years to complete and testing a single compound can cost more than $2 billion. Meanwhile, innumerable animal lives are lost, and the process often fails to predict human responses because traditional animal models often do not accurately mimic human pathophysiology. For these reasons, there is a broad need for alternative ways to...

News 25

Multimedia 7